| Literature DB >> 34155291 |
Elsebeth Lynge1, Hans Asger Holmsgaard2, Therese L F Holmager3, Søren Lophaven4.
Abstract
In a fishing community Thyborøn-Harboøre on the Danish West coast, a chemical factory polluted air, sea, and ground with > 100 xenobiotic compounds. We investigated cancer incidence in the community. A historical cohort was identified from the Central Population Register and followed for cancer incidence in the Danish Cancer Register including inhabitants from 1968-1970 at height of pollution, and newcomers in 1990-2006 after pollution control. Two fishing communities without pollution, Holmsland and Hanstholm, were referent cohorts. We calculated rate ratios (RR) and 95% confidence intervals (CI). In 1968-1970, 4914 persons lived in Thyborøn-Harboøre, and 9537 persons in Holmsland-Hanstholm. Thyborøn-Harboøre had a statistically significant excess cancer incidence compared with Holmsland-Hanstholm; RR 1.20 (95% CI 1.11-1.29) deriving from kidney and bladder cancer; stomach and lung cancer in men, and colorectal cancer in women. In 1990-2006, 2933 persons came to live in Thyborøn-Harboøre. Their cancer incidence was the same as for newcomers to Holmsland-Hanstholm; RR 1.07 (95% CI 0.88-1.30). Persons in Thyborøn-Harboøre at height of chemical pollution had a cancer risk 20% above persons living in non-polluted fishing communities with a pattern unlikely to be attributable to life style. The study suggested that chemical pollution may have affected cancer risk.Entities:
Year: 2021 PMID: 34155291 PMCID: PMC8217208 DOI: 10.1038/s41598-021-92446-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Denmark with the study area Thyborøn-Harboøre and the local control areas Holmsland and Hanstholm marked.
Figure 2Detailed map of Thyborøn-Harboøre. Background map used with permission from The Danish Agency for Data Supply and Efficiency and adapted with details from[4].
Thyborøn-Harboøre and Holmsland-Hanstholm, Denmark. Number of persons, follow-up, person-years, and cancer cases 1968–1970 and 1968–2006.
| Area and period | Number of | Total | Men | Women | |||
|---|---|---|---|---|---|---|---|
| Old cohort: 1968–1970 | Persons | 4914 | 2595 | 2319 | |||
| Mean years of stay | 26.3 | 26.0 | 26.7 | ||||
| Follow-up mean years | 39.5 | 38.3 | 40.8 | ||||
| Person years/Cancers | 194,072 (100%) | 1108 (100%) | 99,490 (100%) | 599 (100%) | 94,582 (100%) | 509 (100%) | |
| 0–39 years | Person years/Cancers | 79,167 (41%) | 37 (3%) | 41,270 (42%) | 16 (3%) | 37,897 (40%) | 21 (4%) |
| 40–59 years | Person years/Cancers | 68,918 (36%) | 300 (27%) | 35,923 (36%) | 139 (23%) | 32,995 (35%) | 161 (32%) |
| 60 + years | Person year/Cancers | 45,987 (24%) | 771 (70%) | 22,297 (22%) | 444 (74%) | 23,690 (25%) | 327 (64%) |
| New cohort: 1990–2006 | Persons | 2933 | 1594 | 1339 | |||
| Mean years of stay | 6.8 | 6.6 | 7.1 | ||||
| Follow-up mean years | 18.5 | 18.4 | 18.6 | ||||
| Person years/Cancers | 54,287 (100%) | 126 (100%) | 29,382 (100%) | 64 (100%) | 24,905 (100%) | 62 (100%) | |
| 0–39 years | Person years/Cancers | 40,807 (75%) | 16 (13%) | 22,018 (75%) | 6 (9%) | 18,789 (75% ) | 10 (16%) |
| 40–59 years | Person years/Cancers | 9689 (18%) | 39 (31%) | 5304 (18%) | 16 (25%) | 4385 (18%) | 23 (37%) |
| 60 + years | Person years/Cancers | 3791 (7%) | 71 (56%) | 2060 (7%) | 42 (66%) | 1731 (7%) | 29 (47%) |
| Old cohort: 1968–1970 | Persons | 9537 | 5001 | 4536 | |||
| Mean years of stay | 20.8 | 21.0 | 20.6 | ||||
| Follow-up mean years | 38.5 | 37.4 | 39.8 | ||||
| Person years/Cancers | 367,492 (100%) | 1869 (100%) | 187,098 (100%) | 1022 (100%) | 180,394 (100%) | 847 (100%) | |
| 0–39 years | Person years/Cancers | 146,790 (40%) | 70 (4%) | 75,411 (40%) | 28 (3%) | 71,379 (40%) | 42 (5%) |
| 40–59 years | Person years/Cancers | 127,443 (35%) | 455 (24%) | 66,032 (35%) | 190 (19%) | 61,411 (34%) | 265 (31%) |
| 60 + years | Person years/Cancers | 93,259 (25%) | 1344 (72%) | 45,655 (24%) | 804 (79%) | 47,604 (26%) | 540 (64%) |
| New cohort: 1990–2006 | Persons | 10,670 | 5615 | 5055 | |||
| Mean years of stay | 5.3 | 5.0 | 5.7 | ||||
| Follow-up mean years | 17.5 | 17.1 | 17.9 | ||||
| Person years/Cancers | 186,222 (100%) | 553 (100%) | 95,888 (100%) | 307 (100%) | 90,334 (100%) | 246 (100%) | |
| 0–39 years | Person years/Cancers | 124,672 (67%) | 63 (11%) | 63,002 (66%) | 27 (9%) | 61,670 (68%) | 36 (15%) |
| 40–59 years | Person years/Cancers | 42,158 (23%) | 190 (34%) | 22,768 (34%) | 88 (29%) | 19,390 (21%) | 102 (41%) |
| 60 + years | Person years/Cancers | 19,392 (10%) | 300 (54%) | 10,118 (11%) | 192 (63%) | 9274 (10%) | 108 (44%) |
Cancer incidence in Thyborøn-Harboøre in 1968–1970 compared with cancer incidence in geographical control group.
| Cancer site | Total | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Nexp+ | Nexp- | RR (95% CI) | Nexp+ | Nexp- | RR (95% CI) | Nexp+ | Nexp- | RR (95% CI) | |
| All cancer | 1108 | 1869 | 1.20 (1.11, 1.29) | 599 | 1022 | 1.19 (1.08, 1.32) | 509 | 847 | 1.20 (1.08, 1.34) |
| All cancer, excl. other skin | 1073 | 1789 | 1.21 (1.12, 1.31) | 576 | 969 | 1.21 (1.09, 1.34) | 497 | 820 | 1.21 (1.08, 1.35) |
| Lip | 6 | 25 | 0.50 (0.20, 1.22) | 21 | |||||
| Oral cavity | 7 | 18 | 0.75 (0.31, 1.79) | 14 | |||||
| Oropharynx | 8 | 8 | 1.94 (0.73, 5.18) | 8 | 6 | 2.58 (0.89, 7.45) | |||
| Oesophagus | 19 | 34 | 1.09 (0.62, 1.91) | 15 | 30 | 0.98 (0.53, 1.82) | |||
| Stomach | 40 | 51 | 1.71 (1.13, 2.59) | 31 | 37 | 1.81 (1.12, 2.92) | 9 | 14 | 1.42 (0.61, 3.31) |
| Small bowel | 6 | ||||||||
| Colon and rectum | 187 | 279 | 1.34 (1.12, 1.62) | 88 | 159 | 1.11 (0.85, 1.44) | 99 | 120 | 1.65 (1.26, 2.15) |
| Colon | 112 | 179 | 1.25 (0.99, 1.59) | 48 | 98 | 0.99 (0.70, 1.39) | 64 | 81 | 1.57 (1.13, 2.19) |
| Rectum | 80 | 104 | 1.53 (1.14, 2.05) | 41 | 62 | 1.32 (0.89, 1.96) | 39 | 42 | 1.83 (1.18, 2.84) |
| Primary liver | 10 | 22 | 0.90 (0.43, 1.90) | 16 | 6 | 6 | 2.08 (0.67, 6.47) | ||
| Pancreas | 30 | 50 | 1.21 (0.77, 1.91) | 19 | 27 | 1.46 (0.81, 2.62) | 11 | 23 | 0.94 (0.46, 1.93) |
| Larynx | 20 | 20 | 1.95 (1.05, 3.63) | 17 | 19 | 1.76 (0.91, 3.39) | |||
| Lung | 181 | 260 | 1.36 (1.12, 1.64) | 119 | 156 | 1.52 (1.19, 1.93) | 62 | 104 | 1.14 (0.83, 1.56) |
| Breast | 142 | 231 | 1.19 (0.97, 1.47) | 139 | 230 | 1.17 (0.95, 1.45) | |||
| Cervix uteri | 17 | 34 | 0.95 (0.53, 1.70) | 17 | 34 | 0.95 (0.53, 1.70) | |||
| Corpus uterus | 29 | 41 | 1.40 (0.87, 2.26) | 29 | 41 | 1.40 (0.87, 2.26) | |||
| Ovary | 26 | 38 | 1.33 (0.81, 2.19) | 26 | 38 | 1.33 (0.81, 2.19) | |||
| Prostate | 107 | 216 | 0.99 (0.78, 1.25) | 107 | 216 | 0.99 (0.78, 1.25) | |||
| Testis | 9 | 14 | 1.19 (0.52, 2.76) | 9 | 14 | 1.19 (0.52, 2.76) | |||
| Kidney | 39 | 38 | 2.07 (1.32, 3.24) | 27 | 28 | 1.92 (1.13, 3.25) | 12 | 10 | 2.48 (1.07, 5.75) |
| Bladder and urinary tract | 107 | 121 | 1.80 (1.39, 2.34) | 82 | 96 | 1.76 (1.31, 2.36) | 25 | 25 | 1.98 (1.14, 3.46) |
| Malignant melanoma | 43 | 61 | 1.35 (0.91, 1.99) | 15 | 17 | 1.68 (0.84, 3.37) | 28 | 44 | 1.22 (0.76, 1.96) |
| Other skin | 56 | 109 | 1.06 (0.77, 1.46) | 37 | 71 | 1.08 (0.73, 1.61) | 19 | 38 | 1.02 (0.59, 1.78) |
| Brain and CNS | 32 | 59 | 1.03 (0.67, 1.59) | 13 | 30 | 0.83 (0.43, 1.59) | 19 | 29 | 1.24 (0.70, 2.22) |
| Non-Hodgkin lymphoma | 32 | 58 | 1.08 (0.70, 1.66) | 16 | 30 | 1.04 (0.56, 1.90) | 16 | 28 | 1.12 (0.60, 2.07) |
| Myelomatosis | 9 | 23 | 0.78 (0.36, 1.68) | 6 | 13 | 0.93 (0.35, 2.44) | 3 | 10 | |
| Leukemia | 30 | 46 | 1.32 (0.83, 2.10) | 22 | 29 | 1.55 (0.89, 2.70) | 8 | 17 | 0.94 (0.41, 2.19) |
| Other specified | 6 | 7 | 1.71 (0.57, 5.11) | ||||||
| Unknown and unspecified | 52 | 95 | 1.15 (0.82, 1.61) | 27 | 54 | 1.07 (0.67, 1.70) | 25 | 41 | 1.25 (0.76, 2.06) |
Number of cancer cases in Thyborøn-Harboøre (Nexp+), number of cancer cases in Holmsland-Hanstholm (Nexp-).rate ratio (RR), and 95% confidence interval (CI). RR adjusted for running age in 5-years age group, 5-year calendar period of follow-up time, and for total also for sex. Blank cell means cancer site not relevant in that sex, or less than 5 observed cases.
Cancer incidence in Thyborøn-Harboøre in 1990–2006 compared with cancer incidence in geographical control group.
| Cancer site | Total | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Nexp+ | Nexp- | RR (95% CI) | Nexp+ | Nexp- | RR (95% CI) | Nexp+ | Nexp- | RR (95% CI) | |
| All cancer | 126 | 553 | 1.07 (0.88, 1.30) | 64 | 307 | 0.94 (0.72, 1.23) | 62 | 246 | 1.23 (0.93, 1.63) |
| All cancer, excl. other skin | 122 | 534 | 1.07 (0.88, 1.30) | 62 | 297 | 0.94 (0.71, 1.23) | 60 | 237 | 1.23 (0.93, 1.64) |
| Colon and rectum | 14 | 60 | 1.19 (0.66, 2.13) | 8 | 34 | 1.23 (0.57, 2.67) | 6 | 26 | 1.16 (0.48, 2.83) |
| Colon | 7 | 32 | 1.13 (0.50, 2.58) | 19 | 13 | ||||
| Rectum | 7 | 29 | 1.16 (0.51, 2.66) | 5 | 16 | 1.56 (0.57, 4.30) | 13 | ||
| Pancreas | 5 | 20 | 1.23 (0.46, 3.29) | 12 | 8 | ||||
| Lung | 23 | 73 | 1.55 (0.97, 2.48) | 10 | 45 | 1.05 (0.53, 2.09) | 13 | 28 | 2.42 (1.25, 4.68) |
| Breast | 16 | 56 | 1.38 (0.79, 2.41) | 16 | 56 | 1.38 (0.79, 2.41) | |||
| Prostate | 10 | 64 | 0.79 (0.40, 1.54) | 10 | 64 | 0.79 (0.40, 1.54) | |||
| Kidney | 5 | 15 | 1.44 (0.52, 3.99) | 11 | 4 | ||||
| Bladder and urinary tract | 11 | 40 | 1.40 (0.72, 2.74) | 7 | 34 | 1.05 (0.46, 2.38) | 6 | ||
| Other skin | 5 | 22 | 1.24 (0.47, 3.27) | 13 | 9 | ||||
| Brain and CNS | 7 | 27 | 1.04 (0.45, 2.39) | 12 | 15 | ||||
Number of cancer cases in Thyborøn-Harboøre (Nexp+), number of cancer cases in Holmsland-Hanstholm (Nexp-), rate ratio (RR), and 95% confidence interval (CI). RR adjusted for running age in 5-years age group, 5-year calendar period of follow-up time, and for total also for sex. Only cancer sites with 5 + cancer cases. Blank cell means cancer site not relevant in that sex, or less than 5 observed cases.